NCT06407310View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

December 1, 2027

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Pembrolizumab

I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles

DRUG

Carboplatin

I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.

DRUG

Paclitaxel

I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.

All Listed Sponsors
lead

Tel Aviv Medical Center

OTHER

NCT06407310 - Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter